Cargando…
Dexamethasone in Patients Hospitalized with COVID-19: Whether, When and to Whom
A clinical interpretation of the Randomized Evaluation of COVID-19 Therapy (RECOVERY) study was performed to provide a useful tool to understand whether, when, and to whom dexamethasone should be administered during hospitalization for COVID-19. A post hoc analysis of data published in the prelimina...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8069656/ https://www.ncbi.nlm.nih.gov/pubmed/33920093 http://dx.doi.org/10.3390/jcm10081607 |
_version_ | 1783683288271945728 |
---|---|
author | Calzetta, Luigino Aiello, Marina Frizzelli, Annalisa Rogliani, Paola Chetta, Alfredo |
author_facet | Calzetta, Luigino Aiello, Marina Frizzelli, Annalisa Rogliani, Paola Chetta, Alfredo |
author_sort | Calzetta, Luigino |
collection | PubMed |
description | A clinical interpretation of the Randomized Evaluation of COVID-19 Therapy (RECOVERY) study was performed to provide a useful tool to understand whether, when, and to whom dexamethasone should be administered during hospitalization for COVID-19. A post hoc analysis of data published in the preliminary report of the RECOVERY study was performed to calculate the person-based number needed to treat (NNT) and number needed to harm (NNH) of 6 mg dexamethasone once daily for up to 10 days vs. usual care with respect to mortality. At day 28, the NNT of dexamethasone vs. usual care was 36.0 (95%CI 24.9–65.1, p < 0.05) in all patients, 8.3 (95%CI 6.0–13.1, p < 0.05) in patients receiving invasive mechanical ventilation, and 34.6 (95%CI 22.1–79.0, p < 0.05) in patients receiving oxygen only (with or without noninvasive ventilation). Dexamethasone increased mortality compared with usual care in patients not requiring oxygen supplementation, leading to a NNH value of 26.7 (95%CI 18.1–50.9, p < 0.05). NNT of dexamethasone vs. usual care was 17.3 (95%CI 14.9–20.6) in subjects <70 years, 27.0 (95%CI 18.5–49.8) in men, and 16.2 (95%CI 13.2–20.8) in patients in which the onset of symptoms was >7 days. Dexamethasone is effective in male subjects < 70 years that require invasive mechanical ventilation experiencing symptoms from >7 days and those patients receiving oxygen without invasive mechanical ventilation; it should be avoided in patients not requiring respiratory support. |
format | Online Article Text |
id | pubmed-8069656 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-80696562021-04-26 Dexamethasone in Patients Hospitalized with COVID-19: Whether, When and to Whom Calzetta, Luigino Aiello, Marina Frizzelli, Annalisa Rogliani, Paola Chetta, Alfredo J Clin Med Brief Report A clinical interpretation of the Randomized Evaluation of COVID-19 Therapy (RECOVERY) study was performed to provide a useful tool to understand whether, when, and to whom dexamethasone should be administered during hospitalization for COVID-19. A post hoc analysis of data published in the preliminary report of the RECOVERY study was performed to calculate the person-based number needed to treat (NNT) and number needed to harm (NNH) of 6 mg dexamethasone once daily for up to 10 days vs. usual care with respect to mortality. At day 28, the NNT of dexamethasone vs. usual care was 36.0 (95%CI 24.9–65.1, p < 0.05) in all patients, 8.3 (95%CI 6.0–13.1, p < 0.05) in patients receiving invasive mechanical ventilation, and 34.6 (95%CI 22.1–79.0, p < 0.05) in patients receiving oxygen only (with or without noninvasive ventilation). Dexamethasone increased mortality compared with usual care in patients not requiring oxygen supplementation, leading to a NNH value of 26.7 (95%CI 18.1–50.9, p < 0.05). NNT of dexamethasone vs. usual care was 17.3 (95%CI 14.9–20.6) in subjects <70 years, 27.0 (95%CI 18.5–49.8) in men, and 16.2 (95%CI 13.2–20.8) in patients in which the onset of symptoms was >7 days. Dexamethasone is effective in male subjects < 70 years that require invasive mechanical ventilation experiencing symptoms from >7 days and those patients receiving oxygen without invasive mechanical ventilation; it should be avoided in patients not requiring respiratory support. MDPI 2021-04-10 /pmc/articles/PMC8069656/ /pubmed/33920093 http://dx.doi.org/10.3390/jcm10081607 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Brief Report Calzetta, Luigino Aiello, Marina Frizzelli, Annalisa Rogliani, Paola Chetta, Alfredo Dexamethasone in Patients Hospitalized with COVID-19: Whether, When and to Whom |
title | Dexamethasone in Patients Hospitalized with COVID-19: Whether, When and to Whom |
title_full | Dexamethasone in Patients Hospitalized with COVID-19: Whether, When and to Whom |
title_fullStr | Dexamethasone in Patients Hospitalized with COVID-19: Whether, When and to Whom |
title_full_unstemmed | Dexamethasone in Patients Hospitalized with COVID-19: Whether, When and to Whom |
title_short | Dexamethasone in Patients Hospitalized with COVID-19: Whether, When and to Whom |
title_sort | dexamethasone in patients hospitalized with covid-19: whether, when and to whom |
topic | Brief Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8069656/ https://www.ncbi.nlm.nih.gov/pubmed/33920093 http://dx.doi.org/10.3390/jcm10081607 |
work_keys_str_mv | AT calzettaluigino dexamethasoneinpatientshospitalizedwithcovid19whetherwhenandtowhom AT aiellomarina dexamethasoneinpatientshospitalizedwithcovid19whetherwhenandtowhom AT frizzelliannalisa dexamethasoneinpatientshospitalizedwithcovid19whetherwhenandtowhom AT roglianipaola dexamethasoneinpatientshospitalizedwithcovid19whetherwhenandtowhom AT chettaalfredo dexamethasoneinpatientshospitalizedwithcovid19whetherwhenandtowhom |